Enveric Biosciences, Inc.

Enveric Biosciences, Inc. (ENVB) is a US-listed equity tracked across major market indices. Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

The company reports trailing twelve-month revenue of $9.60M and net loss of $1.63M. Key metrics include a return on equity of -32.3%, a debt-to-equity ratio of 0.79.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for ENVB to support both active traders and long-term investors.